Tuesday , 28 January 2025
Health

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world.

The post Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World appeared first on MedCity News.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Feb. 10 Virtual Event: The Health Wonk Shop: What’s Next for the Affordable Care Act?

Health coverage enrollment through the Affordable Care Act (ACA) marketplaces now exceeds...

Are ICHRAs Actually Good for Employers and Employees?

ICHRAs are gaining a lot of interest in healthcare. Some say they...

Allara Health’s $26 million Series B raise was led by Index Ventures...

Section 1115 Medicaid demonstration waivers offer states an avenue to test new...